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Abstract
Intrathecal baclofen (ITB) has been known to reduce spasticity which did not respond to oral medications and botulinum toxin
treatment. However, few results have been reported comparing the effects of ITB therapy in patients with cerebral palsy (CP) and
acquired brain injury. This study aimed to investigate beneﬁcial and adverse effects of ITB bolus injection and pump therapy in
patients with CP and to compare outcomes to patients with acquired brain injury such as traumatic brain injury and hypoxic brain
injury. ITB test trials were performed in 37 patients (19 CP and 18 acquired brain injury). Based on ambulatory function, CP patients
were divided into 2 groups: 11 patients with nonambulatory CP and 8 patients with ambulatory CP. Change of spasticity was
evaluated using the Modiﬁed Ashworth Scale. Additional positive or negative effects were also evaluated after ITB bolus injection. In
patients who received ITB pump implantation, outcomes of spasticity, subjective satisfaction and adverse events were evaluated until
12 months post-treatment. After ITB bolus injection, 32 patients (86.5%) (CP 84.2% versus acquired brain injury 88.9%) showed a
positive response of reducing spasticity. However, 8 patients with CP had negative adverse effects. Particularly, 3 ambulatory CP
patients showed standing impairment and 1 ambulatory CP patient showed impaired gait pattern such as foot drop because of
excessive reduction of lower extremity muscle tone. Ambulatory CP patients received ITB pump implantation less than patients with
acquired brain injury after ITB test trials (P= .003 by a chi-squared test). After the pump implantation, spasticity was signiﬁcantly
reduced within 1 month and the effect maintained for 12 months. Seventeen patients or their caregivers (73.9%) were very satisﬁed,
whereas 5 patients (21.7%) suffered from adverse events showed no subjective satisfaction. In conclusion, ITB therapy was effective
in reducing spasticity in patients with CP and acquired brain injury. Before ITB pump implantation, it seems necessary to perform the
ITB bolus injection to verify beneﬁcial effects and adverse effects especially in ambulatory CP.
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11. Introduction
Spasticity or spastic hypertonia accompanied with various
neurological diseases such as cerebral palsy (CP),[1] spinal cord
injury,[2] and acquired brain injury such as traumatic brain
injury[3] has been known to limit the quality of life, function, and
patient care.[4] The ﬁrst way of adjusting spasticity is to take oral
antispasticity medications; however, it is often avoided due to
systemic side effects when used for high-dose oral medication.
Second, focal spasticity can be adjusted by injecting botulinum
toxin, phenol, alcohol, and and so on; however, the antispastic
effects are not permanent. Third, if the above treatments are
ineffective, orthopedic musculoskeletal surgery, selective posteri-
or rhizotomy, intrathecal baclofen (ITB) pump implantation, and
potentially deep brain stimulation can be tried.[4–7]
The baclofen is a GABA receptor agonist that is most
frequently used for the treatment for spasticity. However, the
use has been limited due to systemic side effects such as
drowsiness, confusion, and headache.[8] The ITB therapy can
directly and effectively control spasticity by selectively acting as a
GABA receptor agonist at the phase of the spinal cord with less
systemic side effects.[9,10] Moreover, while orthopedic musculo-
skeletal surgery and selective posterior rhizotomy are irreversible
surgeries, ITB therapy is reversible and continuously controls
spasticity.[11] It has been reported that ITB therapy signiﬁcantly
reduced spasticity which did not respond to oral medications and
[9,10]
Table 1
Baseline characteristics in patients with CP and acquired brain
injury.
Nonambulatory
CP (N=11)
Ambulatory
CP (N=8)
Acquired brain
injury (N=18)
Sex, M:F 9: 2 5: 3 16: 2
Age, years 36.6±2.5 34.1±3.9 33.7±3.6
BMI 19.4±1.6 22.3±1.1 18.4±0.6
Duration, years 36.6±2.5 34.1±3.9 1.7±0.4
∗
MAS
Upper extremity 4.1±0.2 2.6±0.7† 3.6±0.3
Lower extremity 4.2±0.2 2.5±0.5† 3.8±0.3
FIM 54.7±7.1 90.6±11.1
∗
18.2±0.2
MBI 20.5±5.7 58.1±13.4
∗
0
ITBP: No ITBP 7: 4 1: 7 15: 3
BMI=body mass index, FIM= functional independence measure, ITBP= intrathecal baclofen pump,
MAS=modiﬁed Ashworth scale, MBI=modiﬁed Barthel index.
∗
P< .05 compared with the other groups.
† P< .05 compared with nonambulatory CP.
Values are presented as mean±SE.
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reported comparing the immediate effects or long-term effects of
ITB therapy in patients with CP and acquired brain injury.
Among the common cerebral disorders with severe spasticity, it
is difﬁcult to estimate whether the outcomes of ITB was related to
underlying disease.[12] Therefore, the objectives of this research
were to investigate beneﬁcial and adverse effects of ITB bolus
injection and ITB pump therapy in adults with CP and to
compare the outcomes to patients with acquired brain injury such
as traumatic brain injury and hypoxic brain injury. Additionally,
the outcomes of ITB bolus injection were evaluated in patients
with ambulatory CP and nonambulatory CP in this study.
2. Methods
2.1. Subjects
Total 37 patients (30 males and 7 females) with cerebral origin
were recruited in our study. The subjects consisted of 19 CP and
18 acquired brain injury (13 traumatic brain injury and 5 hypoxic
brain injury) (Table 1). All subjects showed spasticity showing
more than grade 2 in theModiﬁed Ashworth Scale (MAS), which
did not effectively respond to oral antispasticity medications.
Average age of subjects was 34.7±2.1 years old. Average
duration of disease was 19.1±3.1 years. Based on ambulatory
function, CP patients were divided into 2 groups; 11 patients with
nonambulatory CP and 8 patients with ambulatory CP. Among
ambulatory CP patients, 4 CP patients could walk outdoors
independently, and 4 CP patients could walk using a gait aid such
as walker. The other 29 patients were wheelchair bounded. The
procedure of this study was approved by the Institutional Review
Board (4-2016-0004).2.2. Intrathecal baclofen test trial and pump implantation
Effects of ITB therapy have been veriﬁed through the test trials of
the ITB bolus injection before ITB pump implantation to decide
the surgery. The ITB bolus injection was provided through
lumbar puncture up to 3 days. If spasticity reduced more than 1
grade in the MAS during the test trial at the most severe limb, it
was regarded as having a deﬁnitive positive response. ITB bolus
injection was usually given 50mg at the ﬁrst day. If there was no2response to the ﬁrst trial, the testing dose was increased to 75mg
at the second day. In this way, 100mg was given at the third day if
the second day dose was ineffective.
For each patient, vital signs and the response of reducing
spasticity measured using the MAS have been closely monitored
2, 4, 6, and 8hours after the ITB bolus injection. Spasticity was
measured in all 4 limbs using the MAS; that is, shoulder
adductors, elbow ﬂexors, and wrist ﬂexors in the upper
extremities and hip adductors, knee ﬂexors, and ankle plantar
ﬂexors in the lower extremities. The MAS grades of right
extremity and left extremity were averaged and the MAS grades
in upper extremity and lower extremity were compared among
groups. For convenience of statistical analysis, as a 5-point
scoring scale, MAS grade 1+ was matched to point 2; grades 2, 3,
and 4 to points 3, 4, and 5, respectively.[13,14] The MAS grade
was selected for analysis when the spasticity reduced most during
the 3 days of the test trials. Beneﬁcial effects such as reducing
dystonic movement, excessive sweating, chronic pain and
improving sitting posture, and adverse effects such as headache,
drowsiness, and generalized hypotonia due to excessive reduction
of muscle tone have been also observed.2.3. Outcome measurement after ITB pump implantation
The ITB pump implantation was operated for the patients who
showed deﬁnitive positive response to the test trials, and no
adverse events. The surgery was conducted after a written
consent and all procedures were operated by experienced
neurosurgeons. After the pump implantation, individual patient
was monitored using the MAS at 3-month intervals to maintain
appropriate dose to control spasticity efﬁcaciously without
adverse effects. The primary outcome after ITB pump implanta-
tion on spasticity using MAS were evaluated as described above
at initial, 1 month, 3 months, 6 months, and 12 months after ITB
pump implantation. Moreover, functional level measured using
the modiﬁed Barthel index (MBI) and functional independence
measure (FIM) were evaluated at initial,1 month, 3 months,
6 months, and 12 months after the pump implantation.
Spasticity and functional levels such as MBI and FIM were
evaluated by physical therapist and occupational therapist special-
ized in the ﬁeld of physical and rehabilitation medicine. Drug side
effects, pump mechanical complications, catheter malfunction, and
baclofen withdrawal symptoms were carefully monitored by
physiatrist and neurosurgeon who had performed the operation.
In addition, the changes of sitting posture and other beneﬁcial or
adverse effects described above were observed. The dosage for
individual administration after the ITB pump implantation was
carefully adjusted within the range of 10% based on the MAS
spasticity grade and other beneﬁcial or adverse effects.
Subjective satisfaction of the patients or caregivers was also
measured from scores of 0 to 10. The point 10 indicated the
highest satisfaction and the point 0 indicated dissatisfaction
which showed that if the score was high, the satisfaction tended to
be high as well. If patients were not able to express their subjective
satisfaction clearly due to cognitive impairment, the satisfaction
of caregivers was measured.2.4. Statistical analysis
Baseline characteristics were compared among nonambulatory
CP, ambulatory CP, and acquired brain injury using one-way
ANOVA, and between the ITB pump group and no ITB pump
group using the independent t-test. After the ITB test trials, the
Table 2
Baseline characteristics in the ITBP Group and No ITBP Group.
ITBP group
(N=23)
No ITBP
group (N=14)
Total
(N=37)
Sex, M: F 20: 3 10: 4 30: 7
Age, years 36.0±2.7 32.3±3.1 34.7±2.1
BMI 18.6±0.6 21.4±1.4 19.6±0.7
Duration, years 14.8±4.0
∗
26.0±4.5 19.1±3.1
MAS
Upper extremity 3.8±0.2 3.1±0.4 3.5±0.2
Lower extremity 3.9±0.3 3.1±0.4 3.6±0.2
FIM 30.0±5.2
∗
65.4±12.1 41.1±5.9
MBI 10.3±3.9
∗
35.1±11.8 18.1±5.0
CP: ABI 8: 15 11: 3
BMI=body mass index, FIM= functional independence measure, ITBP= intrathecal baclofen pump,
MAS=modiﬁed Ashworth scale, MBI=modiﬁed Barthel index.
∗
P< .05 compared with no ITBP group. Values are presented as mean±SE.
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outcomes in patients with CP and acquired brain injury using the
paired t-test. TheMAS grade was also compared using the paired
t-test to investigate the immediate effects after the ITB bolus
injection in the ITB pump group and no ITB pump group.
Descriptive statistics using a chi-squared test were used to
compare the number of nonambulatory CP, ambulatory CP, and
acquired brain injury who received ITB pump implantation after
ITB test trials. In addition, the MAS grade was analyzed to
compare the within-group changes of spasticity using repeated
measures ANOVA after the ITB pump implantation. A P< .05
was considered statistically signiﬁcant.
3. Results
3.1. Comparison of baseline characteristics
The ITB test trials were conducted for total 37 patients (11
nonambulatory CP, 8 ambulatory CP, and 18 acquired brain
injury). When baseline characteristics were compared among
nonambulatory CP, ambulatory CP, and acquired brain injury,
and between the ITB group and no ITB group, there was no
statistical difference in demographic data of gender, age, and
body mass index among groups. However, patients with
acquired brain injury showed shorter disease duration compared
with CP patients (P< .001 by one-way ANOVA). Among CP
patients, ambulatory CP showed lower MAS grade in upper
extremity (P= .034) and in lower extremity (P= .019), and higher
functional levels measured using MBI and FIM (P< .001
respectively) (Table 1).
After ITB test trials, 23 patients (62.2%) (7 nonambulatory
CP, 1 ambulatory CP and 15 acquired brain injury) proceeded to
receive the ITB pump implantation. Patients with CP, particularly
ambulatory CP, received ITB pump implantation less than
patients with acquired brain injury (P= .003 by a chi-squared
test) (Table 1).
On the other hand, when baseline characteristics were
compared between the ITB pump group and patients who did
not receive the pump implantation (no ITB pump group), there
was no statistical difference in gender, age, body mass index, and
MAS spasticity grade. However, the ITB pump group showed
shorter disease duration (P= .027) and lower functional
levels measured using MBI (P= .016) and FIM (P= .003)
(Table 2).
3.2. Effects of intrathecal baclofen test trials
All patients showed beneﬁcial effects such as positive response of
reducing spasticity or other positive effects. Thirty-two patients
(86.5%) (CP 84.2% versus acquired brain injury 88.9%) showed
a deﬁnitive positive response of reducing spasticity after the ITB
test trials. Seventeen patients (45.9%) (CP 68.4% versus acquired
brain injury 22.2%) showed additional beneﬁcial effects such as
decreased dystonic movement, improved sitting posture and sleep
pattern, or decreased excessive sweating and chronic pain.
Among them, 8 patients (21.6%) showed decreased dystonic
movement. Other positive effects were decreased chronic pain in
6 patients (16.2%), improved sitting posture and decreased
excessive sweating in 4 patients (10.8%) respectively, and
improved sleep pattern in 3 patients (8.1%) (Table 3).
Of 14 patients who did not receive the ITB pump implantation
after the test trials, 12 patients showed improved spasticity.
However, 8 patients with CP had negative adverse effects.
Particularly, 3 ambulatory CP patients showed standing3impairment at 50–75mg and 1 ambulatory CP patient showed
impaired a gait pattern such as foot drop during the swing phase
at 50mg because of excessive reduction of lower extremity muscle
tone. In addition, voiding difﬁculty at 100mg, dysarthria at 50m
g, posterior neck pain at 100mg, headache, nausea, and vomiting
at 50mg, and generalized hypotonia at 50mg were shown,
respectively (Table 3). Five patients who showed a reduction of
spasticity without negative adverse effects gave up receiving the
pump implantation due to cost effectiveness and ﬁnancial
difﬁculty.3.3. Spasticity reduction in CP and ABI after intrathecal
baclofen bolus injection
Spasticity reduced both groups of CP and acquired brain injury
after ITP bolus injection. In all subjects, the ITB bolus injection
signiﬁcantly decreased the MAS grade from 3.5±0.2 to 2.7±0.2
in upper extremity and from 3.6±0.2 to 2.7±0.2 in lower
extremity (P< .001 respectively by paired t-tests).
In patients with acquired brain injury, the ITB bolus injection
signiﬁcantly decreased the MAS grade from 3.6±0.3 to 2.6±0.4
in upper extremity (P< .001) (Fig. 1A) and from 3.8±0.3 to 2.7
±0.3 in lower extremity (P= .001) (Fig. 1B). In nonambulatory
CP, the MAS grade also signiﬁcantly decreased after the ITB
bolus injection from 4.1±0.2 to 3.2±0.2 in upper extremity
(P= .001) (Fig. 1A), and from 4.2±0.2 to 3.2±0.2 in lower
extremity (P< .001) (Fig. 1B). However, in ambulatory CP, the
MAS grade signiﬁcantly decrease after the ITB bolus injection in
upper extremity (P= .041) (Fig. 1A), but not in lower extremity
(P= .129) (Fig. 1B).
3.4. Spasticity reduction in ITB pump and no ITB pump
groups after intrathecal baclofen bolus injection
In the ITB pump group, the MAS grade signiﬁcantly decreased
from 3.8±0.2 to 2.8±0.3 in upper extremity (Fig. 2A) and from
3.9±0.3 to 2.9±0.3 in lower extremity (Fig. 2B) (P< .001
respectively by paired t-tests). No ITB pump group also showed
the ITB bolus injection signiﬁcantly decreased the MAS grade
from 3.1±0.4 to 2.4±0.4 in upper extremity (P= .003) (Fig. 2A)
and from 3.1±0.4 to 2.3±0.3 in lower extremity (P= .006)
(Fig. 2B).
When spasticity reduction was also compared between ITB
pump and no ITB pump groups, the MAS grade did not show a
Table 3
Responses of subjects tested with intrathecal baclofen bolus injection.
Spasticity (MAS)
Case Pre Post Positive effects Negative effects ITBP implantation
Nonambulatory CP Upper
Lower
4/4
4/4
3/3
3/3
Improved sitting posture
Decreased excessive sweating
Improved sleep pattern
○
Nonambulatory CP Upper
Lower
4/4
4/4
3/3
3/3
○
Nonambulatory CP Upper
Lower
4/4
4/4
3/3
3/3
Decreased dystonic movement 
Nonambulatory CP Upper
Lower
5/5
5/5
5/5
4/4
Decreased excessive sweating
Decreased chronic pain
○
Nonambulatory CP Upper
Lower
5/4
5/5
3/3
3/3

Nonambulatory CP Upper
Lower
2/4
4/4
1/3
4/3
Decreased dystonic movement
Improved sitting posture
○
Nonambulatory CP Upper
Lower
3/3
4/4
3/3
4/4
Decreased chronic pain
Improved sitting posture
Decreased dystonic movement
○
Nonambulatory CP Upper
Lower
5/4
3/5
4/1
3/4
Improved voluntary movement Voiding difﬁculty at 100mg 
Nonambulatory CP Upper
Lower
5/4
3/5
3/3
2/3
○
Nonambulatory CP Upper
Lower
4/4
3/3
4/4
1/3

Nonambulatory CP Upper
Lower
5/5
5/5
4/4
4/4
Improved sitting posture ○
Ambulatory CP Upper
Lower
5/5
5/5
4/5
4/5
Impaired standing at 75mg 
Ambulatory CP Upper
Lower
0/0
3/3
0/0
1/1
Decreased chronic pain Foot drop during swing phase at 50mg 
Ambulatory CP Upper
Lower
4/4
2/2
3/3
2/2
Decreased chronic pain
Decreased dystonic movement
Impaired standing at 50mg
Dysarthria at 50mg

Ambulatory CP Upper
Lower
4/4
1/2
3/3
1/2
Decreased chronic pain Impaired standing at 75mg 
Ambulatory CP Upper
Lower
2/3
1/1
2/1
0/0
Decreased chronic pain
Decreased dystonic movement
○
Ambulatory CP Upper
Lower
0/0
3/3
0/0
3/3
Decreased dystonic movement Posterior neck pain at 100mg 
Ambulatory CP Upper
Lower
3/3
1/1
3/3
1/1
Decreased dystonic movement Headache, nausea, vomiting at 50mg 
Ambulatory CP Upper
Lower
2/2
4/4
2/2
2/1
Generalized hypotonia at 75mg 
Traumatic brain injury Upper
Lower
4/3
4/4
3/3
3/3
Decreased crying
Improved sleep pattern
○
Traumatic brain injury Upper
Lower
4/4
4/4
4/4
4/4
Decreased excessive sweating
Improved sleep pattern
○
Traumatic brain injury Upper
Lower
4/1
4/3
3/1
3/1

Traumatic brain injury Upper
Lower
5/5
5/5
5/5
4/4
○
Traumatic brain injury Upper
Lower
4/4
5/5
3/4
3/4
○
Traumatic brain injury Upper
Lower
4/1
1/1
3/0
0/0
○
Traumatic brain injury Upper
Lower
5/3
5/5
1/0
4/4
○
Traumatic brain injury Upper
Lower
2/2
1/1
0/0
1/1

Traumatic brain injury Upper
Lower
1/1
4/4
1/1
2/2
○
Traumatic brain injury Upper
Lower
5/5
5/5
3/3
3/3
○
Traumatic brain injury Upper
Lower
3/4
4/4
1/1
0/0
○
(continued )
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Table 3
(continued).
Spasticity (MAS)
Case Pre Post Positive effects Negative effects ITBP implantation
Traumatic brain injury Upper
Lower
3/3
3/3
3/2
3/3
○
Traumatic brain injury Upper
Lower
3/3
2/1
1/1
1/1
○
Hypoxic brain injury Upper
Lower
4/1
3/3
3/1
3/3
○
Hypoxic brain injury Upper
Lower
5/5
5/5
5/5
5/5
Decreased excessive sweating ○
Hypoxic brain injury Upper
Lower
5/5
5/5
4/4
4/4
○
Hypoxic brain injury Upper
Lower
5/5
5/5
3/3
3/3
Improved sitting posture ○
Hypoxic brain injury Upper
Lower
5/4
4/3
4/4
4/3

CP= cerebral palsy, ITBP= intrathecal baclofen pump, MAS=modiﬁed Ashworth scale.
Figure 1. Effects of intrathecal baclofen bolus injection in CP and acquired brain injury. In patients with acquired brain injury, the ITB bolus injection signiﬁcantly
decreased the MAS grade in upper extremity (A) and lower extremity (B). In nonambulatory CP, the MAS grade also signiﬁcantly decreased after the ITB bolus
injection in upper extremity (A) and lower extremity (B). However, in ambulatory CP, the MAS grade signiﬁcantly decreased after the ITB bolus injection in upper
extremity (A), but not in lower extremity (B). ABI=acquired brain injury, CP = cerebral palsy, ITB= intrathecal baclofen, MAS=modiﬁed Ashworth scale.
∗
P< .05,
pre-ITB test trial versus post-ITB test trial.
Figure 2. Effects of intrathecal baclofen bolus injection in ITBP and no ITBP groups. In the ITB pump group, the MAS grade signiﬁcantly decreased in upper
extremity (A) and lower extremity (B). No ITB pump group also showed the ITB bolus injection signiﬁcantly decreased theMAS grade in upper extremity (A) and lower
extremity (B). CP=cerebral palsy, ITBP= intrathecal baclofen pump, MAS=modiﬁed Ashworth scale.
∗
P< .05, pre-ITB test trial versus post-ITB test trial.
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Figure 3. Effects of intrathecal baclofen pump implantation. In all subjects, the ITB pump therapy signiﬁcantly reduced the MAS grade in upper extremity and lower
extremity (A). The beneﬁcial effect was shown signiﬁcantly within 1 month after the implantation andmaintained for a 12month follow-up period. In patients with CP,
the ITB pump therapy signiﬁcantly decreased the MAS grade in upper extremity and lower extremity (B). In patients with acquired brain injury, the ITB pump therapy
also signiﬁcantly decreased the MAS grade in upper extremity and lower extremity (C). CP=cerebral palsy, ITBP= intrathecal baclofen pump, MAS=modiﬁed
Ashworth scale.
∗
P< .05 by repeated measures ANOVA.
Yoon et al. Medicine (2017) 96:34 Medicinedifference between 2 groups, suggesting the reason of no ITB
pump group not proceeding with the pump implantation not
because of little spasticity reduction after the ITB bolus injection,
but because of the negative adverse effects.3.5. Effects of intrathecal baclofen pump implantation
In all subjects, the ITB pump therapy signiﬁcantly reduced the
MAS grade from 3.7±0.2 to 2.2±0.2 in upper extremity and
from 3.9±0.3 to 2.2±0.2 in lower extremity (P< .001
respectively by repeated ANOVA) (Fig. 3A). Looking at Fig. 3
and Table 4, the beneﬁcial effect was shown signiﬁcantly within 1
month after the implantation and maintained for a 12-month
follow-up period. In patients with CP, the ITB pump therapy
signiﬁcantly decreased the MAS grade from 3.9±0.3 to 2.6±0.4
in upper extremity (P= .046) and lower extremity (P= .001)
(Fig. 3B). In patients with acquired brain injury, the ITB pump
therapy also signiﬁcantly decreased theMAS grade from 3.6±0.3
to 2.0±0.3 in upper extremity and from 4.0±0.3 to 2.2±0.3 in
lower extremity (P< .001 respectively) (Fig. 3C).
Seventeen patients (73.9%) among 23 patients who received
the ITB pump implantation were very satisﬁed, showing
subjective satisfaction score was 8.4±0.2 either by the patients
or caregivers. One patient (4.3%) was somewhat satisﬁed
showing subjective satisfaction score was 3. However, 5
patients (21.7%) who were suffered from negative adverse
effects after the pump implantation expressed no satisfaction.
Therefore, overall satisfaction score was 6.3±0.8 out of
maximum score 10.
When the complications after the ITB pump implantation were
evaluated, 8 patients (34.8%) experienced adverse events.
Among them, 4 patients (17.4%) showed reversible adverse
events such as headache, drowsiness, and decreased sitting or
standing balance. Additional 4 patients (17.4%) showed catheter
or wound problems such as catheter disconnection and CSF
leakage, or wound infection, which required revision surgeries.
On the other hand, when the functional outcomes were
evaluated in patients who had received the ITB pump implanta-
tion, the MBI and FIM scores did not signiﬁcantly increase after
the pump therapy (from 9.8±3.9 to 10.4±3.5 inMBI, from 33.6
±5.4 to 34.3±4.8 in FIM). It suggests that ITB pump therapy
could not reverse the functional impairment in patients with
severe disability.64. Discussion
Spasticity causes musculoskeletal deformities and abnormal
posture, which also causes chronic pain and impairs sleep pattern
and activities of daily living.[15] In patients with severe spasticity,
oral antispasticity medications might be insufﬁcient to effectively
manage these symptoms. Botulinum toxin injection can also be
inefﬁcacious to handle generalized spasticity. On the other hand,
it has been veriﬁed that ITB treatment decreases severe
generalized spasticity.[15,16] In this study, most patients showed
a deﬁnitive response of spasticity reduction or other beneﬁcial
effects such as improved sitting posture and sleep pattern, and
decreased excessive sweating and chronic pain after the ITB bolus
injection. Then, the patients who received the ITB pump
implantation showed a signiﬁcant reduction of generalized
spasticity, which was consistent with the previous results.[15,16]
Additionally, patients who did not receive the pump
implantation after ITB test trials continued to take oral
antispasticity medications whereas patients who received the
pump implantation usually reduced the dose of oral antispasticity
medications.
Likewise, the ITB treatment has prominent effects in decreasing
spasticity; however, in safety issues, it has been known that it
could cause side effects such as headache, dizziness, drowsiness,
respiratory depression, seizure, and loss of consciousness.[17–21]
Moreover, catheter-related complications may occur, leading to
increased morbidity and mortality.[22–24] In addition, spasticity
reduction did not always induce functional improvement;
instead, it caused excessive reduction of lower extremity muscle
tone, resulting in instability of walking and standing.[17] Thus, it
is very important to verify functional changes of patients by the
ITB test trials before conducting the ITB pump implanta-
tion.[25,26] In other words, ITB treatment should be selectively
conducted for the cases that are expected to reduce spasticity
without functional impairments. In the CP patients who received
the ITB bolus injection, we also experienced that 3 ambulatory
CP patients showed standing impairment and 1 ambulatory CP
patient showed an impaired gait pattern, similar to a systemic
review[27] reporting that some patients with cerebral origin
compromised their ambulatory and transfer abilities after the ITB
therapy. In addition, 1 patient showed voiding difﬁculty although
he was satisﬁed with spasticity reduction of upper and lower
extremities after the ITB bolus injection; therefore, they did not
proceed to receive the pump implantation.
Table 4
Responses of subjects with intrathecal baclofen pump implantation.
Case
Spasticity (MAS)
Pre 1 month 3 months 6 months 12 months Adverse events Satisfaction (10-point grading scale)
Nonambulatory CP Upper
Lower
4/4
4/4
3/1
3/3
3/1
3/3
3/1
3/3
3/1
3/3
Headache Caregiver 9
Nonambulatory CP Upper
Lower
4/4
4/4
3/3
3/3
4/4
3/3
3/3
1/1
3/3
1/1
Drowsiness
Impaired standing balance
Caregiver 0
Nonambulatory CP Upper
Lower
5/5
5/5
4/3
1/1
4/3
1/1
4/3
1/1
3/3
1/1
Patient 7
Nonambulatory CP Upper
Lower
2/4
4/4
1/3
4/3
1/2
1/2
1/2
1/2
1/2
1/2
CSF leakage Patient 0
Nonambulatory CP Upper
Lower
3/3
4/4
1/1
3/3
1/1
3/3
1/1
3/3
1/1
2/2
Patient 7
Nonambulatory CP Upper
Lower
5/5
5/5
4/4
4/4
3/4
3/3
3/4
3/3
3/4
3/3
Patient 8
Nonambulatory CP Upper
Lower
5/4
3/5
3/3
2/3
3/2
2/3
3/2
3/4
3/2
3/4
Caregiver 8
Ambulatory CP Upper
Lower
3/3
1/1
3/3
1/1
3/3
1/1
4/5
2/2
4/5
2/2
Patient 3
Traumatic brain injury Upper
Lower
4/3
4/4
3/3
3/4
1/1
1/1
1/1
1/1
1/1
1/1
Decreased sitting balance Caregiver 9
Traumatic brain injury Upper
Lower
4/4
4/4
3/3
4/4
3/3
4/4
3/3
4/4
3/3
4/4
Catheter disconnection
Withdrawal symptoms
Caregiver 0
Traumatic brain injury Upper
Lower
5/5
5/5
5/4
4/4
5/5
3/4
5/5
3/4
2/2
3/3
Caregiver 9
Traumatic brain injury Upper
Lower
4/4
5/5
3/4
3/4
4/4
4/4
3/3
4/4
4/3
3/3
Caregiver 9
Traumatic brain injury Upper
Lower
4/1
1/1
1/1
1/1
1/1
1/1
1/1
1/1
1/1
1/1
Caregiver 8
Traumatic brain injury Upper
Lower
5/1
5/5
1/1
3/3
1/1
3/3
1/1
3/3
1/1
3/3
Patient 9
Traumatic brain injury Upper
Lower
1/1
4/4
1/1
2/2
1/1
2/2
1/1
2/2
1/1
2/2
Caregiver 9
Traumatic brain injury Upper
Lower
3/3
4/4
1/1
2/2
1/1
2/2
1/1
1/1
1/1
1/1
Caregiver 9
Traumatic brain injury Upper
Lower
3/3
3/3
3/2
3/3
3/2
3/3
3/2
3/3
3/2
3/3
Caregiver 8
Traumatic brain injury Upper
Lower
5/5
5/5
1/2
1/2
1/0
0/0
1/1
1/1
0/1
0/1
Caregiver 9
Traumatic brain injury Upper
Lower
3/3
2/1
1/1
1/1
2/2
2/0
2/2
2/0
2/2
2/0
Drowsiness Caregiver 0
Hypoxic brain injury Upper
Lower
4/1
3/3
3/3
1/1
3/3
1/1
4/3
1/1
3/2
1/1
Wound infection Caregiver 9
Hypoxic brain injury Upper
Lower
5/5
5/5
4/4
4/4
4/1
3/4
4/3
4/4
3/3
4/4
Wound dehiscence
Catheter disconnection
Caregiver 0
Hypoxic brain injury Upper
Lower
5/5
5/5
4/4
4/4
3/4
4/4
3/3
3/3
3/3
3/3
Caregiver 7
Hypoxic brain injury Upper
Lower
5/5
5/5
3/3
3/3
3/3
3/3
3/3
3/3
3/3
3/3
Caregiver 9
CP= cerebral palsy, MAS=modiﬁed Ashworth scale.
Yoon et al. Medicine (2017) 96:34 www.md-journal.comBecause of the adverse negative effects, CP patients were not
likely to proceed with ITB pump implantation compared to
patients with acquired brain injury although the ITB bolus
injection showed spasticity reduction and other beneﬁcial effects
in both groups. Since the effect on spasticity reductionwas similar
in both groups, difference in proportion of ITB implantation
between 2 groups is more likely related to functionally negative
effects such as impaired standing and gait pattern after the ITB
test trials according to a different baseline functional level.
Patients with acquired brain injury were functionally more severe
than the CP patients in the baseline characteristics, focusing on
the spasticity reduction of extremities and comfort of caregivers.
This implies that baseline function rather than underlying7etiology should be considered more importantly when perform-
ing ITB pump implantation.
After the ITB pump implantation, 1 patient suffered headache
and 1 patient showed decreased sitting balance. Both symptoms
were relieved after modifying the infusion dose of the ITB pump
without altering the antispastic effect. However, 1 patient with
persistent drowsiness eventually wanted to remove the ITB pump.
Therefore, it is essential to effectively adjust the infusion dose to
maximize the beneﬁcial effects while minimizing the negative
adverse events.[28,29] As previous studies reported equipment-
related complications,[22,23,30] we also experienced that 4 patients
out of 23 patients showed catheter-related or wound complica-
tions which required revision management by surgical operation.
[6] Lynn AK, Turner M, Chambers HG. Surgical management of spasticity
Yoon et al. Medicine (2017) 96:34 MedicineAmong them, 3 patients were completely recovered from the
revision surgery. However, 5 patients out of 8 complicated
patients expressed no subjective satisfaction to the ITB pump
implantation. Therefore, it is essential to carefully monitor the
catheter-related complication or other adverse events to solve the
complication as soon as possible.
In our study, we did not ﬁnd a signiﬁcant relationship between
injury duration, spasticity, and functional improvement because
there were not enough patients to compare the outcomes based
on injury duration if the severity of injury was controlled.
However, a recent review regarding the timing of intervention by
Saulino et al[31] described that contrary to the conventional norm
where physicians waited 1 year following brain damage before
performing ITB therapy, early exposure to ITB therapy is safe in
appropriately selected patients. In fact, if the treatment is delayed
for a longer period, musculoskeletal deformities and contracture
may develop. In other literature by Maneyapanda et al,[32] it was
shown that severe generalized spasticity in the earlier phases
following brain injury could interfere with rehabilitation
programs. Taken together, patients with severe spasticity should
consider early application of ITB therapy in order to ease the care,
prevent complications, and improve functional outcomes.
The limitation of this research is the absence of control group
who did not receive the ITB therapy. However, this study
included chronic patients who had consistent spasticity which
had not been effectively controlled by oral medications. In
addition, patients with acquired brain injury were functionally
more severe than the CP patients in the baseline characteristics.
Therefore, it is difﬁcult to directly compare the outcomes between
2 groups because main therapeutic goal might be different; for
example, caregiver convenience rather than functional improve-
ment in patients with acquired brain injury. Further research
should be needed to evaluate the response of a retrial with lower
dose ITB when adverse negative effects are shown after the ITB
bolus injection and to evaluate the outcomes of the ITB pump
treatment for longer periods.
In conclusion, ITB therapy was effective in reducing spasticity
in patients with severe spasticity, although it might have
reversible adverse effects or catheter-related complications and
spasticity reduction did not always induce functional improve-
ments. Before ITB pump implantation, it seems necessary to
perform the ITB bolus injection to verify positive beneﬁcial effects
and negative adverse effects especially in ambulatory CP and
maintain appropriate dose of ITB to control spasticity efﬁca-
ciously without adverse effects after the ITB pump implantation
in patients with CP and acquired brain injury.
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